LiqMeds Group was acquired by Zydus Lifesciences via its subsidiary Zydus Pharmaceuticals U.K. in October 2023. File.
Zydus Lifesciences on Saturday (November 14, 2026) said the U.S. health regulator has concluded its inspection at LiqMeds, U.K., with four observations.
The inspection was conducted from November 9-13, the company said in a regulatory filing to stock exchanges.
“The company will closely work with the U.S. Food and Drug Administration (USFDA) to address the observations expeditiously,” Ahmedabad-based Zydus Lifesciences said.
The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the filing added.
LiqMeds Group was acquired by Zydus Lifesciences via its subsidiary Zydus Pharmaceuticals U.K. in October 2023.
Published – November 14, 2026 03:11 pm IST
